Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05951725 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 17, 2025 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Aug 1, 2024 to Apr 1, 2025v4
  2. Primary completion date: Feb 1, 2024 to Aug 1, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 1, 2023 to Aug 11, 2023
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The combined pertussis, diphtheria and tetanus vaccine, the first vaccine to be included in the Expanded Programme of Immunization(EPI) of World Health Organization(WHO), has played an important role in the prevention and control of these three infectious diseases. The (diphtheria，tetanus and acellular pertussis combined vaccine，DTaP) vaccine was successfully developed in China in 1993, and its safety and serological effects were confirmed by the observation of human safety, with mild vaccination reactions and good immunization effects.The (Diphtheria-tetanus-component acellular pertussis vaccine, DTcP) vaccine is suitable for immunization against pertussis, diphtheria and tetanus infections in people between 2 and 24 months of age.
Trial Details
NCT Number NCT05951725
Lead Sponsor CanSino Biologics Inc.
Conditions
(from sponsor)		 Diphtheria, Tetanus and Acellular Pertussis
Related terms Diphtheria, Tetanus
Enrollment 2,520 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov